InsiderSignal.AI

InsiderSignal.ai

ZBIO - Zenas Biopharma, Inc.

Insider Purchase by Enright Patrick G (Dir)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

4 months ago, Enright Patrick G, serving as Dir at Zenas Biopharma, Inc. (ZBIO), purchased 117,255 shares at $19.19 per share, for a total transaction value of $2,250,027.00. Following this transaction, Enright Patrick G now holds 2,619,189 shares of ZBIO.

This purchase represents a 5.00% increase in Enright Patrick G's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, October 9, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, October 14, 2025, 5 days after the trade was made.

Zenas Biopharma, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Enright Patrick G

Dir

Patrick G. Enright is a seasoned venture capital executive and biopharmaceutical leader, currently serving as a Director at Vera Therapeutics, Inc. (Nasdaq: VERA), where he has been involved since at least 2020 and recently engaged in insider trading activities.[[1]](https://fintool.com/app/research/companies/ZBIO/people/patrick-enright)[[4]](https://www.zoominfo.com/p/Patrick-Enright/1285334097)[[5]](https://www.gurufocus.com/insider/30252/patrick-g-enright) As a co-founder and Managing Director of Longitude Capital since 2006, Enright specializes in healthcare venture investments, with prior roles including Managing Director at Pequot Ventures (2002–2007), where he co-led life sciences investing, and senior executive positions at Valentis Inc., Boehringer Mannheim (Roche), and Sandoz (Novartis).[[1]](https://fintool.com/app/research/companies/ZBIO/people/patrick-enright)[[2]](https://www.curasen.com/patrick-enright-mba/)[[4]](https://www.zoominfo.com/p/Patrick-Enright/1285334097) Enright holds a B.S. in Biological Sciences from Stanford University and an MBA from the Wharton School of the University of Pennsylvania.[[1]](https://fintool.com/app/research/companies/ZBIO/people/patrick-enright)[[2]](https://www.curasen.com/patrick-enright-mba/) His extensive board experience spans over 20 biotech companies, including current directorships at BioAge Labs (Nasdaq: BIOA), Jazz Pharmaceuticals (Nasdaq: JAZZ), and Zenas BioPharma, as well as past roles at Aimmune Therapeutics (acquired by Nestlé), Corcept Therapeutics, and Vaxcyte.[[1]](https://fintool.com/app/research/companies/ZBIO/people/patrick-enright)[[2]](https://www.curasen.com/patrick-enright-mba/)[[4]](https://www.zoominfo.com/p/Patrick-Enright/1285334097) He owns approximately 5.1 million shares of Vera Therapeutics as a 10% owner, reflecting significant investment commitment.[[5]](https://www.gurufocus.com/insider/30252/patrick-g-enright)

View full insider profile →

Trade Price

$19.19

Quantity

117,255

Total Value

$2,250,027.00

Shares Owned

2,619,189

Trade Date

Thursday, October 9, 2025

136 days ago

SEC Filing Date

Tuesday, October 14, 2025

Filed 5 days after trade

HEALTHCAREBIOTECHNOLOGY

About Zenas Biopharma, Inc.

Company Overview

No company information available
View news mentioning ZBIO

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/759321

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime